1,2-Dichloroethane → HCID 57944963, Verbindung

HRID 548004

Reaktionsgleichung

Reaktionsgleichung von HRID 548004
Cl.[CH3:2][C:3]1[C:7]([CH2:8][N:9]2[CH:13]=[C:12]([NH2:14])[CH:11]=[N:10]2)=[C:6]([CH3:15])[O:5][N:4]=1.[N:16]1[CH:21]=[CH:20][CH:19]=[CH:18][C:17]=1[C:22](O)=[O:23].C1C=CC2N(O)N=NC=2C=1.C(N(CC)CC)C.C(Cl)CCl>C(Cl)Cl>[CH3:2][C:3]1[C:7]([CH2:8][N:9]2[CH:13]=[C:12]([NH:14][C:22](=[O:23])[C:17]3[CH:18]=[CH:19][CH:20]=[CH:21][N:16]=3)[CH:11]=[N:10]2)=[C:6]([CH3:15])[O:5][N:4]=1

Komponenten

7

Versuchsvorschrift

1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-amine hydrochloride (example 4-1a) (400 mg, 2.1 mmol), picolinic acid (256 mg, 2.1 mmol), and HOBt (388 mg, 2.50 mmol) were mixed in DCM (7 mL). The reaction was treated with triethylamine (670 mL, 4.8 mmol) and stirred for 15 minutes at room temperature under a nitrogen atmosphere. EDC (598 mg, 3.1 mmol) was added and the reaction was stirred for an additional 4 hours. The reaction was then diluted with dichloromethane (5 mL) and washed with aqueous saturated NaHCO3 solution (5 mL, 2×) and then with aqueous saturated NaCl solution (5 mL). The organic layer was collected, dried, and filtered. Solvents were removed under vacuum. The crude product was re-suspended in EtOH (5 mL) and purified by reversed phase HPLC (5%-95% ACN in H2O:25 minute gradient). The pure fractions were combined and concentrated to afford N-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)picolinamide (372 mg, 60%) as a white solid. 1H NMR (CDCl3, 400 MHz): δ 2.21 (s, 3H), 2.44 (s, 3H), 5.05 (s, 2H), 7.49-7.47 (m, 1H), 7.59 (s, 1H), 7.93-7.88 (dt, J=14, 2 Hz, 1H), 8.07 (s, 1H), 8.24-8.21 (d, J=8 Hz, 1H), 8.61-8.56 (m, 1H), 9.83 (bs, 1H). LC/MS; [M+H] calculated for C15H15N5O2; expected 297.1; found 298.3. Melting point: 135-137° C.

Aufarbeitung

  1. stirringthe reaction was stirred for an additional 4 hours
  2. washwashed with aqueous saturated NaHCO3 solution (5 mL, 2×)
  3. customThe organic layer was collected
  4. customdried
  5. filtrationfiltered
  6. customSolvents were removed under vacuum
  7. custompurified by reversed phase HPLC (5%-95% ACN in H2O:25 minute gradient)
  8. concentrationconcentrated

Quellen und Nachweise

ORD-Eintrag
ord-35a30dc54e5a48e3a865bc8f047f763e
Quelldatensatz
uspto-grants-2011_05
Patentnummer
US07939671B2

Verknüpfte Notizen

Wird geladen…